Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
Revolution Medicines (NASDAQ:RVMD), a late-stage clinical oncology company, has announced significant leadership appointments to strengthen its development and commercial capabilities. Dr. Alan Sandler joins as Chief Development Officer, bringing extensive oncology expertise from his previous roles at ALX Oncology, Mirati Therapeutics, and Genentech.
The company has also appointed Alicia Gardner as SVP and General Manager for the U.S. region and Gerwin Winter as SVP and General Manager for Europe. These appointments align with Revolution Medicines' preparation for potential approvals and commercial launches of daraxonrasib for RAS-driven cancers, including pancreatic ductal adenocarcinoma.
Revolution Medicines (NASDAQ:RVMD), una società oncologica in fase avanzata, ha annunciato importanti nomine per rafforzare le capacità di sviluppo e commerciali. Il Dott. Alan Sandler entra come Chief Development Officer, portando una vasta esperienza in oncologia maturata in ALX Oncology, Mirati Therapeutics e Genentech. L’azienda ha inoltre nominato Alicia Gardner come SVP e General Manager per la regione degli Stati Uniti e Gerwin Winter come SVP e General Manager per l’Europa. Queste nomine allineano Revolution Medicines con la preparazione a potenziali approvazioni e lanci commerciali di daraxonrasib per tumori driven by RAS, inclusi l’adenocarcinoma duttale pancreatico.
Revolution Medicines (NASDAQ:RVMD), una empresa de oncología en etapa avanzada, ha anunciado importantes nombramientos para reforzar sus capacidades de desarrollo y comerciales. El Dr. Alan Sandler se incorpora como Chief Development Officer, aportando amplia experiencia en oncología de sus funciones previas en ALX Oncology, Mirati Therapeutics y Genentech. La compañía también ha designado a Alicia Gardner como SVP y Gerente General para la región de Estados Unidos y a Gerwin Winter como SVP y Gerente General para Europa. Estos nombramientos respaldan la preparación de Revolution Medicines para posibles aprobaciones e lanzamientos comerciales de daraxonrasib para cánceres impulsados por RAS, incluido el adenocarcinoma ductal pancreático.
리볼루션 파마슈티컬스(Revolution Medicines, NASDAQ:RVMD)는 개발 및 상업 역량 강화를 위한 중대한 리더십 임명을 발표했습니다. 알란 샌들러 박사가 Chief Development Officer로 합류하여 ALX Oncology, Mirati Therapeutics 및 Genentech에서의 종양학 전문 지식을 가져옵니다. 또한 회사는 미국 지역 SVP 겸 총지배인으로 Alicia Gardner, 유럽 지역 SVP 겸 총지배인으로 Gerwin Winter을 임명했습니다. 이 임명은 RAS 구동 암에 대한 가능성 있는 승인 및 daraxonrasib의 상용 출시를 준비하는 Revolution Medicines의 전략과 일치합니다. 이는 췌관선암을 포함합니다.
Revolution Medicines (NASDAQ:RVMD), une entreprise de oncologie en phase avancée, a annoncé des nominations clés pour renforcer ses capacités de développement et de commercialisation. Le Dr Alan Sandler rejoint comme Chief Development Officer, apportant une vaste expérience en oncologie acquise lors de ses postes précédents chez ALX Oncology, Mirati Therapeutics et Genentech. L’entreprise a également nommé Alicia Gardner comme SVP et Directrice générale pour la région États‑Unis et Gerwin Winter comme SVP et Directeur général pour l’Europe. Ces nominations s’inscrivent dans la préparation de Revolution Medicines à d’éventuelles approbations et lancements commerciaux de daraxonrasib pour les cancers pilotés par le RAS, y compris l’adénocarcinome canalaire pancréatique.
Revolution Medicines (NASDAQ:RVMD), ein Unternehmen der späten klinischen Onkologie, hat bedeutende Führungswechsel angekündigt, um Entwicklungskapazitäten und kommerzielle Fähigkeiten zu stärken. Dr. Alan Sandler tritt als Chief Development Officer bei und bringt umfassende onkologische Erfahrung aus seinen bisherigen Positionen bei ALX Oncology, Mirati Therapeutics und Genentech mit. Das Unternehmen hat außerdem Alicia Gardner als SVP und General Manager für die Region USA sowie Gerwin Winter als SVP und General Manager für Europa ernannt. Diese Ernennungen entsprechen der Vorbereitung von Revolution Medicines auf potenzielle Zulassungen und Markteinführungen von daraxonrasib für RAS-getriebene Krebserkrankungen, einschließlich des pankreatischen Duktalen Adenokarzinoms.
أعلنت Revolution Medicines (المدرجة في ناسداك: RVMD)، وهي شركة أبحاث سريرية متقدمة في مجال الأورام، عن تعيينات قيادية مهمة من شأنها تقوية قدراتها في التطوير والتسويق. ينضم الدكتور ألان ساندلر بوصفه Chief Development Officer، وهو يملك خبرة واسعة في علم الأورام من مناصبه السابقة في ALX Oncology وMirati Therapeutics وGenentech. كما عينت الشركة أليسيا غاردنر بصفة نائب رئيس أول ومدير عام للمنطقة الأمريكية وغرفين وينتر كنائب رئيس أول ومدير عام لأوروبا. تتماشى هذه التعيينات مع استعداد Revolution Medicines لاحتمال الموافقات وإطلاق daraxonrasib لعلاج أنواع السرطان المرتبطة بـ RAS، بما في ذلك سرطان البنكرياس القادري القنال.
Revolution Medicines（纳斯达克股票代码：RVMD），一家处于晚期临床阶段的肿瘤学公司，宣布了一系列重要的领导层任命，以加强其开发与商业化能力。Alan Sandler博士加入担任首席开发官，带来他在ALX Oncology、Mirati Therapeutics和Genentech等公司的丰富肿瘤学经验。公司还任命Alicia Gardner为美国区高级副总裁兼总经理，任命Gerwin Winter为欧洲区高级副总裁兼总经理。这些任命与 Revolution Medicines 为潜在的批准与daraxonrasib在RAS驱动的癌症市场（包括胰腺导管腺癌）上市做准备的计划相一致。
- Strategic expansion of leadership team with experienced oncology expert Dr. Alan Sandler as CDO
- Establishment of regional commercial infrastructure with new U.S. and European general managers
- Preparation for potential commercial launches of daraxonrasib for RAS-driven cancers
- None.
REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe.
“I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “As a physician-scientist, Alan is recognized as a leader in the field of lung cancer and has established a track record of excellence in oncology drug development. He brings valuable additional leadership to our organization as the scope and maturity of our development activities grow in support of advancing our compelling pipeline of distinguished clinical-stage RAS(ON) inhibitors on behalf of patients.”
Dr. Sandler joins Revolution Medicines from ALX Oncology, where he most recently served as chief medical officer. Prior to joining ALX Oncology, he was executive vice president and chief medical officer at Mirati Therapeutics through its acquisition by Bristol Myers Squibb. Previously, he served as president and head of global development, Oncology at Zai Lab Limited, and earlier held senior leadership roles at Genentech, a member of the Roche Group, where he drove multiple oncology development programs. Alan has also held academic leadership roles as division chief of Hematology/Oncology at Oregon Health and Science University, medical director of Thoracic Oncology at Vanderbilt University, and medical director of the Thoracic Oncology Program at Indiana University.
As a further step in building global commercial capabilities, Revolution Medicines has also appointed two key regional leaders: Alicia Gardner as senior vice president, general manager for the U.S. region, and Gerwin Winter as senior vice president, general manager for the European region. Alicia and Gerwin will play important leadership roles as the company prepares for the potential approvals and commercial launches of daraxonrasib in patients with cancers driven by RAS, including pancreatic ductal adenocarcinoma, as well as other innovative targeted medicines for patients living with RAS-addicted cancers.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding the company’s development plans and timelines and its ability to advance its portfolio and R&D pipeline, its vision to develop new global standards of care and the potential approval and commercial launch of the company’s product candidates. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ current stage of development, the process of designing and conducting preclinical and clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
Who is the new Chief Development Officer at Revolution Medicines (RVMD)?
What are the key leadership appointments announced by Revolution Medicines (RVMD)?
What is Revolution Medicines (RVMD) preparing for with these new appointments?
What is Dr. Alan Sandler's background before joining Revolution Medicines (RVMD)?
